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Background: Long acting bronchodilators are the standard of care in the management of chronic obstructive
pulmonary disease (COPD). The aim of this study was to investigate the efficacy and safety of V0162, a novel
anticholinergic agent with bronchodilator properties, in preclinical models and in patients with COPD.
Methods: Guinea pigs were used to evaluate the impact of V0162 on the acetylcholine or histamine-induced
bronchoconstriction. V0162 was also investigated in an allergic asthma model on ovalbumin-sensitized guinea pig.
For clinical investigations, healthy volunteers were included in a dose-escalation, randomized, placebo-controlled
phase I study to determine the maximal tolerated dose, followed by a randomized, placebo-controlled, cross-over
phase II study in patients with COPD. V0162 was given via inhalation route. The objectives of the phase I/II study
were to assess the safety and efficacy of V0162, in terms of bronchodilation and reduction in hyperinflation.
Results: Preclinical results showed that V0162 was able to prevent bronchoconstriction induced either by
acetylcholine or histamine. V0162 reversed the bronchoconstriction and airway inflammation caused by ovalbumin
challenge in sensitized guinea pigs. In the healthy volunteers study, 88 subjects were enrolled: 66 received V0162
and 22 received placebo. No particular safety concerns were raised. The maximal tolerated dose was not reached
and the dose escalation was stopped at 2400 μg. A total of 20 patients with COPD were then enrolled. All patients
received a single-dose of V0162 1600 μg and of placebo in two alternating periods. In COPD patients, V0162
demonstrated a significant increase in FEV1 compared with placebo (148 ± 137 ml vs. 36 ± 151 ml, p = 0.003).
This bronchodilatory effect was corroborated by a reduction in hyperinflation. There was a trend toward dyspnea
relief (change in visual analog scale at 22 h, −15.1 ± 26.0 mm vs.- 5.3 ± 28.8 mm with placebo, p = 0.054). No serious
adverse events (AEs) were reported. Most common AEs were productive and non-productive cough, dyspnea
and pruritus.
Conclusions: V0162 improved pulmonary function and tended to improve dyspnea in patients with COPD over
more than 24 h. The slight plasmatic exposure observed might support the good safety profile.
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Chronic obstructive pulmonary disease (COPD) is a pro-
gressive debilitating condition and a leading cause of
morbidity and mortality [1]. This common preventable
and treatable disease is characterized by a persistent air-
flow limitation that is usually progressive and associated
with an enhanced chronic inflammatory response in the
airways and the lung to noxious particles or gases. Symp-
toms include dyspnea, chronic cough and sputum produc-
tion. Exacerbations and comorbidities contribute to the
overall severity in individual patients [2].
Inhaled bronchodilators are the cornerstone of symp-
tomatic management of COPD [2]. According to the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD), long-acting β2-agonists and anticholinergics
are preferred over short-acting formulations in patients
with persistent dyspnea [2]. Currently most available in-
haled long-acting bronchodilators provide between 12-
and 24-h duration of action. Of these, tiotropium was
the first available long-acting anticholinergic agent pro-
viding 24 h of bronchodilation [3–7]. Tiotropium is as-
sociated with sustained reduction in lung hyperinflation
and significant improvement in exertional dyspnea [7].
In the large UPLIFT study (Understanding Potential
Long-Term Impacts on Function with Tiotropium), treat-
ment with tiotropium over 4 years was associated with im-
provement in lung function and quality of life, and with
reduced mortality, particularly cardiovascular mortality
[8–10]. Tiotropium was also associated with a decreased
risk of exacerbations and related hospitalizations [9].
However, tiotropium did not significantly reduce the glo-
bal rate of decline in FEV1, but tended to prevent the de-
cline in post-bronchodilator FEV1 in patients with GOLD
stage II COPD [10]. A recent meta-analysis also suggested
that when compared with ipratropium bromide, tiotro-
pium was associated with improved lung function and
quality of life, and fewer CODP-related exacerbations
and associated hospitalizations [11].
Novel long-acting muscarinic receptor antagonists
(LAMAs) are currently in clinical development for the
treatment of COPD or asthma, and some were recently
approved and brought to the market for the treatment
of COPD (e.g. glycopyrronium, aclidinium) [12]. Glyco-
pyrronium and aclidinium are expected to produce similar
improvement in lung function, dyspnea, quality of life and
exacerbation compared to tiotropium [13–15].
V0162 inhalation powder is a new anticholinergic
compound derived from mequitazine, an existing oral
racemic antihistamine commercialized for over 30 years.
The molecular formula for V0162 is 10-[(3R)-1-azabi-
cyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine and its
molecular weight is 322 g/mol. V0162 is the dextrorota-
tory enantiomer of mequitazine. Mequitazine is an anti-
histaminic with one of the highest affinity for muscarinicreceptors in the nanomolar range [16, 17]. V0162 is devel-
oped under a pharmaceutical formulation different than
that of the parent compound and at a lower dose for
inhalation. In in vitro metabolism studies, a marked differ-
ence was observed between the levorotary and the dextro-
rotatory enantiomers, assuming that these latter involve
different metabolic pathways. V0162 is currently under in-
vestigation mainly for the treatment of COPD.
The present paper reports results from preclinical ex-
periments and clinical phase I/II study assessing the ef-
ficacy and safety of V0162. The aim of this study was to
assess (i) the bronchodilatory and anti-inflammatory
properties of V0162 in preclinical models, (ii) its safety
in healthy volunteers and, (iii) and its effect on pul-





Animals were handled and cared in accordance with the
European Directive 86/609, and the protocols were car-
ried out in compliance with French regulations and with
local Ethical Committee guidelines for animal research
(CEA-CEPC N°110).
Animal model for acetylcholine- and histamine-induced
bronchoconstriction
Male Guinea pigs, weighing 400–450 g and divided into
groups of 7–9 animals, were anaesthetized with 60 mg/
kg of pentobarbital sodium. Four fifths (4/5th) were ad-
ministered intraperitonealy (i.p) and the remaining fifth
subcutaneously. The jugular vein and trachea were cannu-
lated; to suppress spontaneous respiratory movements,
animals were paralyzed with intravenous administration of
gallamine triethioride (10 μg/kg; 1 mL/kg). The broncho-
pulmonary function was measured according to Konzett
& Rossler’s modified method [18]. Briefly, the animals
were ventilated by means of a sinusoidal pump (Ugo
Basile) at constant pressure and with a constant volume in
excess (5 mL) and a frequency of 90 strokes/min. The ex-
cess of air that did not ventilate the lung was measured by
a transducer. An intravenous administration of acetylcho-
line or histamine induced a bronchoconstriction that was
measured by the increase of recorded air volume in ex-
cess; the recorded ‘so-called’ residual volume (mL) corre-
sponded to the difference between the air pump (5 mL)
and the air inspired by the animal. Ventilatory parameters
were recorded continuously for 75 min (IOX2, EMKA
Technologies, Paris).
Bronchoconstriction was induced by intravenous (i.v.)
acetylcholine (20 μg/kg) or histamine (7 μg/kg), prior to
a single intratracheal administration of the study drug
(V0162), tiotropium (Spiriva®, Boehringer Ingelheim) or
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using the Dry Powder Insufflator Model DP-4 (Penn-
Century Inc). Successive i.v. injections of acetylcholine
or histamine were performed 5, 10 and 15 min before
the intratracheal administrations (to obtain basal values)
and 5, 15, 30 and 60 min after the intratracheal adminis-
trations of either VO162or tiotropium. The experiment
was not extended beyond 60 min since both the effects
of V0162 and tiotropium reached a plateau, as previ-
ously shown for tiotropium [19].Ovalbumin-induced bronchoconstriction and lung
inflammation in Guinea pigs
Ovalbumin-sensitized guinea pigs represent a relevant
animal model to assess the effect of V0162 on both
bronchoconstriction and inflammation [20]. Male Guinea
pigs (250–300 g, 11–16 animals per group) were sensi-
tized by bilateral i.p. injections of ovalbumin (100 μg) and
aluminum hydroxide (100 mg) in 1 ml of physiological
serum on Day 1, followed by a booster injection on Day 5
[20]. On Day 15, an ovalbumin challenge was carried out
with a nebulized solution of ovalbumin (200 μg in 1 ml of
physiological serum). Single intratracheal administrations
of V0162 (50 μg), tiotropium (3 μg), budesonide (800 μg,
Pulmicort®, Astrazeneca,) or vehicle were performed
15 min before the ovalbumin challenge, under a slight
isoflurane anesthesia. Ventilatory parameters were mea-
sured before and one hour post-challenge, using whole
body plethysmography (Emka, Technologies, Paris). The
“enhanced pause” (PenH) AUC value, which represents
the index of bronchopulmonary resistance, was calculated
using the following formula (peak expiratory flow / peak
inspiratory flow) x pause. Although we assume that the
use of PenH to assess pulmonary function has been chal-
lenged, it is actually one of the classical parameter used in
many publications [21]. The whole body plethysmography
does not allow for residual volume measurement as per-
formed in the Konzett and Rossler experiments on venti-
lated anesthetized animals.
Bronchoalveolar lavages (BAL) were performed after
euthanasia 24 h post-challenge. A tracheotomy was
performed and saline was gently infused into the lung;
after recovery, samples were centrifuged and pellets
suspended in 1 ml of saline. Total number of leukocytes
was counted with ADVIA 2120i Hematology System
(Siemens Diagnostics).Phase I/II study
This phase I/II combined study consisted of dose escal-
ation study assessing the safety in healthy volunteers,
followed by a proof-of-concept study assessing the effi-
cacy and safety of V0162 in COPD patients (Clinical-
Trials.gov identifier: NCT01348555).Subjects
Eligible subjects for the healthy volunteers study were
males aged between 18 and 50 years, with a body mass
index (BMI) ranging from 18 to 30 kg/m2.
Eligible patients for the COPD study were men or post-
menopausal women aged between 40 and 75 years, BMI
between 18 and 35 kg/m2, having a post-bronchodilator
forced expiratory volume in 1 s (FEV1) ≥30 % and <80 %
predicted, a post-bronchodilator FEV1/forced vital cap-
acity (FVC) <70 %, with a smoking history of ≥ 10 pack-
year and lung hyperinflation defined as a functional
residual capacity (FRC) greater than 120 %.
Subjects with past or current history of asthma, or
other significant respiratory conditions, or who had ex-
perienced an exacerbation within the last 6 weeks, were
excluded from the study. Subjects with abnormal vital
signs, or abnormal laboratory findings, or clinically rele-
vant ECG abnormalities, or cardiovascular conditions
prior to screening were also excluded from the study.
All subjects provided written informed consent prior
to study participation. The study was conducted in France
and Belgium. The protocol was approved in France by the
“Comité de Protection des Personnes Ile de France VI Pitié
Salpêtrière” (Approval n° 3–11) and the French National
Agency for Medicine and Health Products Safety (Ap-
proval n° A110118-77), and in Belgium by the Institutional
Review Board ZNA/OCMW of Antwerp (EC Approval n°
3945) and the Federal Agency for Medicines and Health
Products (Approval n° 380756).
Study design
The healthy volunteers study was randomized, placebo-
controlled, double blind with escalating-dose design. At
each dose level, subjects were randomly assigned 3:1 to
receive either a single-dose of V0162 (n = 6) or placebo
(n = 2) (Fig. 1).
Additionally, study drug (V0162 or placebo) was co-
administered with activated charcoal (Toxicarb®, SERB) to
prevent the digestive absorption, as presented in Fig. 1.
The COPD study was randomized, placebo-controlled,
double-blind, double-dummy cross-over study consisting
of three periods. All patients were given both a single-
dose of V0162 1600 μg and placebo in two alternating pe-
riods of time during the study (Fig. 1). The study drug was
packed into hard capsules for use in dry powder inhalers
(DPIs). In a third single-blind period, all patients received
tiotropium (Spiriva® 18 μg delivered via HandiHaler®,
Boehringer Ingelheim), the mainstay of COPD treatment.
At this stage of development, it was decided to use a very
easy-to-handle device, “the RS01 monodose” (Plastiape,
Spa.). This DPI is a low resistance device reaching a pres-
sure drop of 4 kPa at 100 L/min. Nevertheless, its per-
formance when used to deliver V0162 could be optimized
in the future, given that the fine particle dose (FPD) is
Fig. 1 Phase I and Phase II study design
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with other marketed DPIs providing a FPD up to 45 %
of the nominal dose [22]. Obviously, DPI performance
should be improved in the next clinical development
stages of V0162.
Assessments
Pulmonary function tests (PFT) were performed at inclu-
sion, over the first 12 h following treatment administration
in healthy volunteers and over the first 32 h after treat-
ment administration in COPD patients, and at the end-of-
study visit. PFT consisted of spirometry (MasterScope®,
Jaeger) in healthy volunteers and plethysmography (Mas-
terScope Body®, Jaeger in France and BodyBox®, MediSoft
in Belgium) in COPD patients, performed according to
the American Thoracic Society/European Respiratory So-
ciety (ERS/ATS) guidelines. Along with PFT, dyspnea was
evaluated by the patient using a 20 cm bidirectional visual
analog scale (VAS) ranged from “-10 to +10”, with −10 for
“Improvement in dyspnea”, 0 for “No dyspnea” and +10
“Intolerable dyspnea”. Blood sampling was performed toassess the pharmacokinetics (PK) of V0162 in healthy vol-
unteers and in COPD patients.
In both studies, general safety parameters included AEs,
vital signs, physical examination, clinical laboratory safety
tests and electrocardiograms (12-lead ECG). In addition,
24-h holter (ECG) were performed in healthy volunteers.
End points
In the healthy volunteers study, the primary objective
was to assess the safety of V0162. Secondary end-points
included PK parameters (Cmax, tmax, AUC0-t, AUC0-∞) and
changes in FEV1.
In the COPD study, the primary objective was to
evaluate the bronchodilator effect of V0162. The primary
end-point was the change in the time-normalized area
under the curve of FEV1 over the period from 30 min to
9 h post-dose (AUC30min/9 h) between V0162 and pla-
cebo. Time -normalized AUCs (expressed in mL) were
calculated as AUC over a given period of time (expressed
in mL*h) divided by the duration of the period (expressed
in h). Other end-points were FEV1 AUC30min/9 h of
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functional residual capacity (FRC), dyspnea and safety.
Trough FEV1 was defined as the lowest value observed
between 30 min and 32 h. Dyspnea was evaluated using
the net incremental area under the curve (nIAUC),
which represents the AUC below the baseline value.
Statistical analysis and sample size calculation
In preclinical experiments evaluating induced-
bronchoconstrition, a mixed model with treatment,
as fixed factor and time as repeated measure, was per-
formed. Time x treatment interactions were tested also.
Baseline values were used as covariates (MIXED proced-
ure in SAS R9.3). For the plethysmograph analyses, a one-
way ANOVA followed by a Dunn’s test was performed.
The healthy volunteers study was an exploratory dose-
escalation study; it was therefore conducted in a con-
venient population sample without prior sample size
calculation.
For the COPD study, 20 patients were required to de-
tect a mean difference of 150 mL in FEV1 AUC30min/9h
between V0162 and placebo (SD 200 mL; within-subject
correlation coefficient 0.75) with 88 % of power at a
two-sided significance level of 0.05.
Descriptive statistics, including mean ± standard error
(SE) and changes from baseline were provided. In the
healthy volunteers study, statistical analysis was performed
on FEV1 change from baseline. In the COPD study, the
FEV1 AUC30min/9h was compared between V0162 and pla-
cebo in a mixed linear model for cross-over designs, as
proposed by Kenward and Roger [23]. The adjusted means
(LS mean) for treatment groups were provided with their
95 % CI. Given the study design, there were no compari-
sons planned between tiotropium and study drugs (V0162
or placebo).
Results
V0162 effects on acetylcholine- and histamine-induced
bronchoconstriction in Guinea pigs
A Guinea pig model of bronchoconstriction induced by
acetylcholine or histamine was used to assess the anti-
bronchoconstrictor effect of V0162. In untreated Guinea
pigs, residual volume (RV) was generally between 1.4
and 2.0 ml (data not shown). During acetylcholine- and
histamine-induced bronchoconstriction, the increase in
the RV (up to 3.8–4 mL) was prevented and even a
dose-dependent decrease of RV was obtained after the
single intratracheal administration of V0162 (Fig. 2a, b).
The maximal effect was reached at 15 min with 25 μg of
V0162 after acetylcholine-induced bronchoconstriction
(a 53 % significant decrease from baseline, p < 0.05), and
with 50 μg of V0162 in histamine-induced bronchocon-
striction (46 % significant decrease from baseline, p <
0.05). The bronchodilator effect of V0612 was maintainedup to 60 min. Tiotropium (3 μg) exhibited anti-
bronchoconstrictor properties, slightly larger than V0162
facing the acetylcholine challenge, but of lower magnitude
than V0162 during the histamine challenge (Fig. 2). At
60 min, the mean inhibition of the acetylcholine-
induced bronchoconstriction was 14 %, 37 % and 26 %
for V0162 5 μg, 25 μg and 50 μg respectively, and 50 %
for tiotropioum 3 μg, compared with vehicle (lactose).
The mean inhibition of the histamine-induced broncho-
constriction was 13 %, 18 % and 24 % by V0162 5 μg,
25 μg and 50 μg, respectively, and 12 % by tiotropium
3 μg, compared with vehicle.
V0162 effects in ovalbumin-induced bronchoconstriction
in Guinea pig
A single intratracheal administration of V0162 in sensitized
animals decreases significantly the ovalbumin-induced
bronchoconstriction compared with vehicle (Fig. 2-c). The
PenH AUC was reduced by 68 %, almost half an hour after
a single intratracheal administration of V0162 at 50 μg,
and a comparable effect was obtained with tiotropium (a
decrease of 53 % in PenH AUC). Budesonide did not re-
duce significantly the intensity and the duration of the
bronchoconstriction.
Twenty four hours post-challenge, vehicle-treated Guinea
pigs showed a massive leukocyte infiltration (18 985 ± 1
368/ mm3 in BAL fluid). This inflammatory response was
partially prevented by V0162 (50 μg), tiotropium (3 μg)
and budesonide (800 μg) in a similar manner (Fig. 2-d).
A reduction of 27 %, 30 % and 27 % was observed in
total leukocytes with V0162, tiotropium and budeso-
nide, respectively.
Enrollment and patient disposition
In the healthy volunteers study, 153 male subjects were
screened and 88 were randomized (Fig. 1). No significant
differences were found in baseline characteristics be-
tween dose cohorts In the COPD study, 37 patients were
screened and 20 were randomized (Fig. 1). Subjects’ char-
acteristics are presented in Table 1. There was no prema-
ture withdrawal throughout all the study.
Safety
In both studies, there were no serious AEs reported.
In the healthy volunteers study, the maximal toler-
ated dose (MTD) was not reached. Taking into account
the large number of inhalations, the dose escalation
was stopped at 2400 g (12 capsules/24 inhalations)
which was considered as the MAD with the current
study drug formulation (200 μg per capsule). Thirteen
AEs were reported in 9 healthy volunteers (Table 2). Of
these, 9 events were considered as related to the study
drug in 7 subjects.
Fig. 2 Bronchoprotection and anti-inflammatory effects of intratracheal V0162 single-dose in preclinical models. a Effect over time of V0162 and
tiotropium on bronchoconstriction induced by acetylcholine in Guinea pigs, b Effect over time of V0162 and tiotropium on bronchoconstriction
induced by histamine in Guinea pigs. Data are expressed as mean ± SEM. *p < 0.05 vs. vehicle (A and B, mixed model with treatment, as fixed
factor and time as repeated measure. Baseline values were used as covariates). c Effect of V0162, tiotropium and budesonide on pulmonary
resistance in ovalbumin-sensitized Guinea pigs. d Effect of V0162, tiotropium and budesonide on the total number of leukocytes in BAL performed
24 h post-challenge. Data are expressed as mean ± SEM. *p < 0.05 vs. vehicle (c and d, one-way ANOVA followed by a Dunn’s test)






Age, years 31.3 ± 8.8 60.4 ± 5.5
BMI, kg/m2 24.4 ± 2.9 24.5 ± 4.4
Time since diagnosis, years NA 5.9 ± 4.4 (0.1–15.8)
Never smokers 75 -
Former smokers 13 20
Tobacco consumption,
pack-years
NA 47.5 ± 25.1
FEV1, L 4.15 ± 0.53 1.23 ± 0.53
FEV1 (% predicted) 97.71 ± 10.28 43.40 ± 15.16
FVC, L 5.05 ± 0.66 2.76 ± 0.83
FVC (% predicted) 118.95 ± 13.76 98.03 ± 20.66
FEV1/FVC, % 82.43 ± 5.52 43.84 ± 10.41
FRC (% predicted) - 180.28 ± 44.10
RV (% predicted) - 220.71 ± 62.15
RV/TLC (% predicted) - 164.86 ± 22.15
Results are presented by mean ± SD (min-max) or number of patients (n)
NA not applicable
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tients: 42 experienced with V0162, 28 with placebo and
23 with tiotropium (Table 2). Twenty-six AEs were re-
lated to the treatment in 9 COPD patients.
Most frequent AEs reported with V0162 were cough
(10/20 in patients with COPD and 3/66 in health volun-
teers), dyspnea (7/20), productive cough (6/20) and prur-
itus (3/20 and 1/66). All these experienced AEs were
mild to moderate in severity; none had led to study drug
discontinuation.
In both healthy volunteers and COPD patients, no
relevant changes from baseline were observed in phys-
ical examination, vital signs, body weight, 12-lead ECG
parameters or in laboratory parameters. Although some
COPD patients presented abnormalities on QTcF re-
gardless of the study product, the only one clinically sig-
nificant abnormality was already present at baseline, and
consequently was not related to the study drug. V0162 did
not led to cardiac abnormalities in healthy volunteers, nor
in COPD patients. As shown below in PK results, the
Cmax was very low (2 ng/mL), and the compound was
quickly eliminated regardless of the dose, thus preventing
systemic anticholinergic side effects.
Table 2 Treatment-emergent AEs in healthy volunteers and COPD patients
COPD patients Healthy volunteers
Placebo (n = 20) V0162 (n = 20) Tiotropium (n = 20) Placebo (n = 22) V0162 (n = 66)
Adverse event Event n Patients n (%) Event n Patients n (%) Event n Patients n (%) Event n Patients n (%) Event n Patients n (%)
Total 28 8 (40) 42 16 (80) 23 12 (60) 6 4 (18) 7 5 (8)
Cough 7 4 (20) 14 10 (50) 7 6 (30) 1 1 (4.5) 3 3a (4.5)
Dyspnea 5 4 (20) 8 7 (35) 6 4 (20) - - - -
Productive Cough 7 4 (20) 6 6 (30) 4 4 (20) - - - -
Headache 3 3 (15) 3 3 (15) 3 3 (15) 3b 3 (13.6) - -
Throat Irritation 1 1 (5) 3 3 (15) 1 1 (5) 1 1 (4.5) - -
Wheezing 1 1 (5) 2 1 (5) 1 1 (5) - - - -
Pruritus - - 3 3 (15) - - - - 1 1c (1.5)
Abdominal pain 1 1 (5) - - - - - - 1 1c (1.5)
Angina Pectoris - - - - 1 1 (5) - - - -
Dizziness 1 1 (5) - - - - - - - -
Erysipelas 1 1 (5) - - - - - - - -
Erythema 1 1 (5) - - - - - - - -
Fatigue - - 1 1 (5) - - - - - -
Diarrhea - - 1 1 (5) - - - - - -
Dry Mouth - - 1 1 (5) - - - - - -
Nausea - - - - - - 1 1 (4.5) 1 1d (1.5)
Epistaxis - - - - - - - - 1 1e (1.5)
A patient with multiple AEs is counted only once
a2 subjects at 1200 μg and 1 at 2400 μg
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In healthy volunteers study, there was no significant
change in FEV1 between V0162 and placebo. However,
an increase in FEV1 was observed with V0162 1200 μg
compared with placebo (0.84 L, 95 % CI [−15; 183]);
the difference not reaching the statistical significance
(p = 0.094).
In the COPD study, V0162 improved significantly the
FEV1 AUC30min/9 h of 0.10 ± 0.03 L (95%CI: 0.04–0.16),
compared with placebo. This was also the peak effect
observed at 9 h. V0162 exhibited a long-lasting bron-
chodilator effect maintained up to 32 h after inhalation
(Fig. 3-a). FEV1 AUC30min/22h, FEV1 AUC30min/28h and
FEV1 AUC30min/32h changes from placebo were of 0.09 ±
0.03 L, 0.08 ± 0.03 L and 0.09 ± 0.03 L, respectively
(Table 3). The difference in trough FEV1 between
V0162 and placebo was 0.08 ± 0.03 L, p = 0.016.
A similar pattern was observed for FVC and FRC. The
mean values for FVC and FRC over time are presented
in Fig. 3b, c, respectively. Compared with placebo, V0162
had statistically significant improved FVC AUC30min/9 h,
FVC AUC30min/22 h and FVC AUC30min/32 h (Table 3).The V0162 effect on FRC AUC30min/9 h and AUC30-
min/22 h showed a significant decrease of 0.262 L (p <
0.001) and 0.177 L (p = 0.006) compared with placebo, re-
spectively (Table 3). No significant reduction in VR was
observed with V0162.
V0162 tended to reduce dyspnea ratings as compared
with placebo, without reaching statistical significance: the
decrease in nIAUC30min/9 h and nIAUC30min/22 h was
of −7.15 ± 3.9 mm (p = 0.084) and −7.7 ± 3.75 mm (p =
0.054, respectively (Table 3 & Fig. 3-e)).
Tiotropium showed a pronounced bronchodilator ef-
fect in patients with COPD: LS mean of FEV1 AUC30-
min/9 h was 1.50 ± 0.12 L. At trough, tiotropium FEV1
was 1.32 L. This benefit was maintained up to 32 h: FEV1
AUC30min/22 h, FEV1 AUC30min/28 h and FEV1
AUC30min/32 h were 1.47 L, 1.46 L and 1.7 L, respect-
ively. FVC AUC30min/9 h and AUC30min/22 h were
3.28 L and 3.21 L, respectively. Like V0162, tiotropium
tended to reduce dyspnea as compared with placebo,
without reaching a statistical significance: nIAUC30-
min/9 h and nIAUC30min/22 h were −16.2 ± 5.2 mm
(NS) and −16.2 ± 5.8 mm (NS), respectively.
Fig. 3 a Mean values and standard error (SE) of FEV1, b mean values and SE of FVC, c mean values and SE of FRC, d change from baseline of
dyspnea (VAS mm) over time (from 0 to 32 h) and SE, in placebo- and V0162-treated COPD patients. (V0162 1600 μg, n = 20)
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PK parameters are summarized in Table 4. Following a
single-dose of V0162 administered by oral inhalation in
healthy volunteers, the maximum plasma level (Cmax)
was reached between 0.08 and 0.10 h post-dose, followed
by a rapid decrease (Fig. 4). Second increase in plasma
levels was observed between 0.75 h and 8 h post-dose.
This later increase was not observed when digestive a-
bsorption was blocked with activated charcoal. A long
elimination phase was observed, with mean t1/2 varying
between 17.4 h and 36.9 h post-dose. The AUCs ratio of
V0162 + charcoal/V0162 alone suggested that digestive
absorption contribute to 42–48 % of the overall V0162
absorption, beside the pulmonary absorption. Cmax and
AUC0-∞ were nonlinear across the range of tested doses.
In cohorts ranging from 50 to 2400 μg, when the dose in-
creased by two-fold, Cmax and AUC0-∞ increased by 2.17
and 2.03-fold, respectively. There was no significant statis-
tical difference in PK parameters between V0162 2400 μg
alone and combined with ipratropium/fenoterol.
Like in healthy volunteers, Cmax in COPD patients was
reached at 0.08 h post-dose and a second peak was ob-
served, followed by a long elimination phase. Mean Cmax
was 54 % lower in COPD patients compared with
healthy volunteers.
Discussion
Our preclinical studies showed that V0162 not only re-
verses bronchoconstriction induced either by acetylcho-
line or histamine, but also prevents ovalbumin-inducedbronchoconstriction and lung inflammation. In animal
models, particularly in ovalbumin-sensitized animals,
specific muscarinic antagonists have been shown to exert
anti-inflammatory activities with reduction in airway
smooth muscle thickening and fibrosis, airway hyper-
responsiveness, mucous gland hypertrophy, Th2 cytokine
production and eosinophil infiltration [24–27]. In a recent
large clinical study, tiotropium used as add-on therapy re-
duced the risk of severe exacerbation in asthmatic patient
who have symptoms despite standard treatments [28].
Based on these results, tiotropium has been recently
approved by the regulatory authorities in the EU, as an
add-on maintenance bronchodilator treatment in adult
asthmatic patients currently treated with the maintenance
combination of inhaled corticosteroids and long-acting
beta2-agonists, and who experienced one or more severe
exacerbations in the previous year.
The efficacy of V0162 in reversing histamine-induced
bronchoconstriction and its anti-inflammatory effect in
the ovalbumin-sensitized animal model are also likely re-
lated to the antihistaminic properties of mequitazine, the
parent compound. Antihistamines have been actually
shown to exert anti-inflammatory activities in allergen-
sensitized animal models [29–33]. A meta-analysis of
clinical trials in asthma has suggested that antihistamines
induce bronchodilation in comparison with placebo; but
this effect was of limited magnitude and the systemic ef-
fects observed after repeated use of antihistamines do not
support the use of these medications alone in the treat-
ment of asthma [34]. Through an inhalation route, the risk
Table 3 Pharmacodynamic parameters in COPD patients
treated with V0162 versus placebo
COPD patients
V0162 (n = 20) Placebo (n = 20) p-value
FEV1
AUC30min/6h, L 1.36 ± 0.13 1.26 ± 0.11 0.004
AUC30min/9h, L 1.36 ± 0.12 1.26 ± 0.12 0.003
AUC30min/22h, L 1.33 ± 0.12 1.24 ± 0.12 0.006
AUC30min/28h, L 1.34 ± 0.12 1.25 ± 0.12 0.007
AUC30min/32h, L 1.35 ± 0.12 1.27 ± 0.12 0.006
Trough FEV1, L 1.19 ± 0.11 1.11 ± 0.11 0.016
FVC
AUC30min/6h, L 3.01 ± 0.20 2.86 ± 0.18 0.019
AUC30min/9h, L 3.01 ± 0.19 2.87 ± 0.19 0.011
AUC30min/22h, L 2.96 ± 0.18 2.83 ± 0.18 0.017
AUC30min/28h, L 2.96 ± 0.19 2.84 ± 0.18 0.013
AUC30min/32h, L 2.98 ± 0.19 2.85 ± 0.19 0.014
FRC
AUC30min/6h, L 5.24 ± 0.23 5.45 ± 0.29 <0.001
AUC30min/9h, L 5.25 ± 0.25 5.51 ± 0.25 <0.001
AUC30min/22h, L 5.34 ± 0.24 5.52 ± 0.24 0.006
AUC30min/28h, L 5.21 ± 0.24 5.43 ± 0.29 0.003
AUC30min/32h, L 5.22 ± 0.24 5.41 ± 0.29 0.003
Dyspnea
nIAUC30min/6h, mm - 17.79 ± 5.26 - 11.44 ± 5.27 0.161
nIAUC30min/9h, mm - 18.08 ± 5.31 - 10.93 ± 5.31 0.084
nIAUC30min/22h, mm - 17.45 ± 5.97 - 9.72 ± 5.97 0.054
nIAUC30min/28h, mm - 17.33 ± 6.04 - 9.43 ± 6.04 0.057
nIAUC30min/32h, mm - 17.45 ± 6.03 - 10.193 ± 6.03 0.078
Results are presented by mean ± SE
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like V0162 as shown in the present PK and safety results.
The blockade of H1 histamine receptors by V0162 in
the airways is likely to induce a weak bronchodilating ef-
fect, in addition to the bronchodilating effect related to
the blockade of M3 muscarinic receptors. The potential
additive (even synergistic) bronchodilating effect of com-
pounds acting by different mechanisms on the airway
smooth tone has been documented previously [35–38].
Altogether, the anti-histaminic properties of V0162 could
confer benefit particularly in asthma, in addition to the
main anticholinergic-related bronchodilation observed
in COPD patients and to the potential anticholinergic-
related anti-inflammatory activities.
The properties of V0162 were similar to those ob-
served with tiotropium but at higher tested doses. At
similar doses, V0162 had less prominent effect than tio-
tropium on bronchoconstriction induced by acetylcho-
line. This difference could be explained by the fact thatthe affinity of V0162 at muscarinic receptors according
to the affinity of mequitazine [16, 39] may be about 100-
fold lower than that of tiotropium.
Our clinical results showed that a single-dose of
V0162 induces sustained bronchodilation in patients
with COPD, as evidenced by statistically significant im-
provement in FEV1 compared with placebo, maintained
up to 32 h [40–42]. This improvement was clinically
relevant since the minimal clinically important differ-
ence of 100 ml was achieved at the peak effect. [40–42].
The results observed were slightly different from the
assumed hypothesis; the observed difference in FEV1
AUC30min/9 h was actually smaller and the variability
was lower. However, these findings led to clinically and
statistically significant results. The positive impact on
the FEV1 was consistent with the benefit observed on
the reduction of hyperinflation and on dyspnea as assessed
by patients. The observed effect of tiotropium was in ac-
cordance with those found in literature [8]. This finding
confirms the reliability of the observed effects. No direct
comparisons were performed between tiotropium and
V0162 due to the study design.
The tested dose throughout the COPD study was
1600 μg, although the MAD was 2400 μg in the dose-
escalation study. Lower dose was considered to minimize
the treatment burden, given the relatively high number of
capsules (200 μg each) and inhalations (2 per capsule).
The purpose was to assess the bronchodilator properties
of the compound. However, the performance of the aero-
dynamic properties remains under investigation. Aerosol
particle size emitted from the DPI is one of the most im-
portant variables in defining drug delivery [43, 44]. Fine
particles with aerodynamic diameter ≤ 5 μm are essential
to ensure optimal drug deposition and distribution. Cur-
rently, the fine particle dose (FPD), defined as the dose of
the fine particles in the emitted aerosol, is quiet low (al-
most 15 % of the nominal dose with the current DPI).
The use of an optimized DPI can increase the FDP up to
45 % [45] (+diffuse study), leading to an increase in pul-
monary deposition and potentially to an improvement
in the deposition in distal airways according to the par-
ticle sizes [46–48].
The administration of activated charcoal combined
with V0162 showed that digestive absorption contrib-
utes significantly to the overall bioavailability: V0162 is
absorbed at the gastrointestinal tract, with approximately
42 to 48 % of the overall absorption. A rapid pulmonary
absorption was observed few minutes after inhalation
(which corresponded also to the Cmax) and was followed
by a digestive absorption observed 8 to 12 h later.
Although maximal plasmatic concentration was reached
rapidly, V0162 exhibited low systemic exposure (at the
picomolar range) with a long-lasting half-life (up to 36 h).
Topical administration via the inhalation route allows a
Table 4 V0162 pharmacokinetic parameters for different dose cohorts in healthy volunteers and in COPD patients
V0162 dose tmax (h) Cmax (pg/mL) AUC0-t (h.pg/mL) t1/2 (h)
Healthy volunteers Median Mean SD Mean SD Mean SD
10 μg nc nc nc nc nc nc nc
50 μg 0.08 40 14 555 790 26 13
100 μg 0.08 108 41 1872 1981 19 0.69
200 μg 0.08 149 33 4578 2633 28 11
400 μg 0.08 431 268 6529 3774 23 8.08
800 μg 0.08 1030 311 17670 13735 19 4.88
1200 μg 0.08 2180 2030 17646 12297 20 11
1600 μg 0.08 2270 618 32692 13447 36 15
2000 μg 0.08 2970 1800 41192 37151 19 3.55
2400 μg 0.10 2840 1040 26820 16211 17 3.40
100 μg + charcoal 0.08 98 65 560 250 21 3.99
200 μg + charcoal 0.08 81 28.8 1483 411 32 13
400 μg + charcoal 0.08 359 216 3541 1871 27 8.32
2400 μg + ipratropium/fenoterol 0.11 2600 824 31200 9941 19 4.17
COPD patients
1600 μg 0.08 1040 577 13872.8 6461 nc nc
nc not calculated (more than 50 % of plasma values were below the lower limit of quantification (5.00 pg/mL)
Fig. 4 Mean plasma concentration over 72 h after a single dose of V0162 50 μg, 100 μg, 200 μg, 400 μg, 800 μg, 1200 μg, 1600 μg, 2000 μg,
2400 μg in healthy volunteers s (log/linear scale)
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out leading to high systemic exposure. Consequently po-
tential systemic adverse events, including cholinergic side
effects and cardiovascular events, may be prevented. Mean
maximal plasmatic concentration was almost two-fold
lower in COPD patients compared with healthy volun-
teers. This finding may be due to the underlying disease.
In fact, airway narrowing and reduction in the inspiratory
flow may alter lung deposition [43].
As a result, V0162 was well tolerated with a good over-
all safety profile. No serious AEs were reported and all
AEs were mild in severity. Most frequent AEs included
productive and non-productive cough, dyspnea and prur-
itus. These observed AEs are consistent with previous
reports on inhaled bronchodilators; common AEs are gen-
erally a result of the patient’s preexisting condition and of
the route of administration [49–51]. There was no dose–
response relationship between V0162 and AEs. Laboratory
findings, vital signs and ECG observations were un-
changed during the study. No particular electrocardio-
graphic change was observed. The V0162 plasma levels
appear 50-fold lower than the concentration threshold
(330 nM) that may cause hERG cardiac toxicity.
Given the exploratory nature of this study, this latter is
potentially limited by its sample size, the single-dose set-
ting, the short-duration, and the use of a non-optimized
DPI. Nevertheless, it is the first clinical investigation
which asses the safety and efficacy of V0162 in human.
Larger phase II studies with longer study duration, other
study designs and optimized formulations are on-going.
Conclusions
Inhaled V0162, given at 1600 μg single-dose, resulted in
statistically significant long-lasting bronchodilation that
reached the minimal clinically important difference
threshold for FEV1 at the peak effect, and positive safety
profile in patients with moderate-to-severe COPD. At
this stage of development, the choice of the tested dose
was based on safety data, and does not correspond to
the minimal effective dose. A phase II dose-finding study
is required to estimate the minimal effective dose. Given
the activity of V0162 as an antagonist of muscarinic recep-
tors and its additional activities (e.g. anti-histamine activ-
ity), this compound would be of interest for the treatment
of COPD and potentially also of asthma as recently shown
with tiotropium, a pure LAMA. More clinical investiga-
tions in these two respiratory diseases are yet needed.
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